Moving Ahead: More ADC Progressing Through the Clinic and Beyond Oncology and Hematology
This week from September 20-22, 2017, the 8th World ADC, the industry’s leading forum, discussing the latest developments and...
What Governments Can Do To Address Cancer
While much work remains to find a cure for cancer – the good news is we know that many...
A Call to Action: Submit Your Expertise
Valuable lessons learned from both approved antibody-drug conjugates (brentuximab vedotin /Adcetris®; Seattle Genetics approved in 2011 and ado-trastuzumab emtansine...
More ADC Targets Emerging, But They are Taking Longer to Commercialize
The Antibody-drug Conjugate (ADC) field remains an exciting area and Piramal is privileged to be in a great location...
Death of the Great Laboratory of Clinical Medical Science
Free-market capitalism has brought unimaginable innovations to mankind in the last 200 years, more so than any other economic...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New...
Can the President Still Cure Cancer?
Forty- five years ago, in a room filled with congressional members from both sides of the isle, distinguished guests,...
Early Detection: The New Cancer Paradigm
A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good...
Contract Manufacturing of Antibody-drug Conjugates – A Growing Market
The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal...
Developing the Next Generation of Clinically Successful Antibody-drug Conjugates
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers...
